ONCY

Oncolytics Biotech Inc

• TipRanks·5d ago

  Oncolytics Showcases Pelareorep Phase 2 mCRC Study Plans

• Benzinga·5d ago

  Oncolytics Biotech To Present Trail-In-Progress Abstract, E-Poster For Its REO 033 Trial At European Society For Medical Oncology

• TipRanks·5d ago

  Oncolytics to present REO 033 trial in progress abstract at ESMO

• NASDAQ·10/14 16:21

  Oncolytics Updates GOBLET Study Data Timelines, Expects Final PanCAN Grant Payment

• TipRanks·10/14 13:57

  Oncolytics Biotech Updates GOBLET Gastrointestinal Cancer Study

• Benzinga·10/14 13:32

  Oncolytics Biotech Anticipates Reporting Final Results From Group 4 Of Its GOBLET Phase 1/2 Trial In Q4 For Pelareorep With Atezolizumab To Treat Squamous Cell Anal Carcinoma; To Receive Payment Under Grant From Pancreatic Cancer Action Network This Quarter

• TipRanks·10/14 12:45

  Oncolytics should be bought amid recent weakness, says Lake Street

• NASDAQ·10/13 08:50

  Oncolytics Expands Pelareorep Patent Strategy With New Method-of-Use Filings

• TipRanks·10/12 20:32

  Oncolytics Biotech Extends Pelareorep Patent Protection Into Late 2040s

• TipRanks·10/12 20:15

  Oncolytics provides intellectual property portfolio update

• Benzinga·10/12 20:08

  Oncolytics Biotech Expands Pelareorep Patent Protection Strategy Through 2044

• NASDAQ·09/30 11:33

  Oncolytics Highlights Pelareorep Preclinical Findings In Hepatocellular Carcinoma

• TipRanks·09/29 14:00

  Oncolytics Biotech Highlights Pelareorep’s Tumor-Activating Potential

• TipRanks·09/29 13:45

  Oncolytics announces publication of data on pelareorep in liver cancer

• Benzinga·09/29 13:33

  Oncolytics Biotech Publishes Data On Pelareorep Immunotherapy In Proceedings Of The National Academy Of Sciences